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A B S T R A C T
Objective: The objective of this study was to compare the diagnostic yield of GeneXpert MTB/RIF with
Ziehl-Neelson (ZN) sputum smear microscopy among index TB cases and their household contacts.
Methods: A cross sectional study was conducted among sputum smear positive index TB cases and their
household contacts in Northern Ethiopia.
Results: Of 353 contacts screened, 41 (11%) were found to have presumptive TB. GeneXpert test done
among 39 presumptive TB cases diagnosed 14 (35.9%) cases of TB (one being rifampicin resistant),
whereas the number of TB cases diagnosed by microscopy was only 5 (12.8%): a 64.3% increased
positivity rate by GeneXpert versus ZN microscopy. The number needed to screen and number needed to
test to diagnose a single case of TB was signiﬁcantly lower with the use of GeneXpert than ZN
microscopy. Of 119 index TB cases, GeneXpert test revealed that 106 (89.1%) and 5 (4.2%) were positive
for rifampicin sensitive and rifampicin resistant TB, respectively.
Conclusion: GeneXpert test led to increased TB case detection among household contacts in addition to
its advantage in the diagnosis of Rifampicin resistance among contacts and index TB cases. There should
be a consideration in using GeneXpert MTB/RIF as a point of care TB testing tool among high risk groups.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Background
Globally, there were an estimated 9.6 million incident cases
of TB in 2014. The best estimate of the case detection rate for all
forms of TB globally in 2014 was 63%, whereas 3.6 million
cases remained undetected1. The cases that remained undetect-
ed continue to suffer from TB disease and also transmit the
disease to their contacts2. The regions that contributed for most
of the undetected all-forms incident TB cases are south-east Asia
and Africa3. The passive TB case ﬁnding has contributed
signiﬁcantly in the identiﬁcation and management of TB cases* Corresponding author.
E-mail addresses: dhabte@msh.org, derejehabte@yahoo.com (D. Habte).
http://dx.doi.org/10.1016/j.ijid.2016.07.002
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).presenting to health facilities3,4. There is still the need to exert
further efforts geared toward improving TB case ﬁndings and
possibly identify the undetected TB cases that would have been
missed while using the conventional passive TB case ﬁnding
approaches5–7.
The World Health Organization (WHO) recommends system-
atic screening for active TB with the aim of early detection of TB
cases and prompt treatment that ensures better treatment
outcome and reduced TB transmission to contacts8. There is a
strong recommendation that household contacts and other close
contacts should be systematically screened for active TB8,9. The
globally recommended initial diagnostic tests for presumptive TB
cases identiﬁed among contacts were either sputum smear
microscopy to identify acid fast bacilli (AFB) or a rapid molecular
test like GeneXpert MTB/RIF8,9.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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in the 2014/15 ﬁscal year with a case detection rate of 67%10. In
Ethiopia, TB case ﬁnding was mainly focused on passive case
ﬁnding at health facilities and referrals by community health
workers which were able to detect up to two-third of the annually
estimated TB cases11. To improve the TB case ﬁnding, one of the
new approaches recommended by the national TB program is TB
screening among close and household contacts of infectious TB
cases. The ﬁrst line laboratory test for presumptive TB cases
identiﬁed in the contact screening is sputum smear microscopy
while GeneXpert MTB/RIF test is also recommended if the index TB
case is a drug resistant TB patient or is at risk of harboring drug
resistant TB11.
The national GeneXpert MTB/RIF implementation guideline
recommends its use among presumptive MDR TB cases that include
symptomatic contacts of MDR-TB cases, and presumptive TB cases
among HIV positive individuals and children below 14 years of
age12. Studies have been conﬁrming that GeneXpert MTB/RIF test
had signiﬁcantly higher yield than sputum smear microscopy in
different settings including Ethiopia13–15. However, the wider
decentralization and use of GeneXpert MTB/RIF in low income
countries needs to be evaluated in terms of its cost, ongoing
supplies, maintenance issues and the need for uninterrupted
electric supplies. There is also a need to demonstrate the added
advantage of GeneXpert MTB/RIF over conventional sputum smear
microscopy in different settings including contacts16,17. Studies that
compared the yield of GeneXpert MTB/RIF with smear microscopy
among contacts of index TB cases are scarce.
In this study, the diagnostic yield of GeneXpert MTB/RIF was
compared with that of Ziehl-Neelson (ZN) sputum smear
microscopy among index TB cases and their household contacts.
2. Methods
2.1. Study design and setting
A cross sectional study was conducted among sputum smear
positive index TB cases and their household contacts. The study
was done at eleven TB diagnostic and treatment health centers in
North Gondar zone of Amhara region, Ethiopia between May
2013 and April 2015. North Gondar Zone has a total population of
3.6 million with TB case notiﬁcation rate of 119 per 100,000
population (Unpublished data, Management Sciences for Health,
2015). There are three hospitals and 133 public health centers
providing TB prevention and control services in the zone. Health
centers are operated by Nurses, Health Ofﬁcers, Laboratory
Technicians, Pharmacy Technicians and administrative staff. The
eleven health centers included in the study were selected as they
are closer to Gondar University Hospital so that sputum specimens
for GeneXpert test could be transported easily. These health
centers have been participating in the external quality assurance
(EQA) program of the country for ZN microscopy. The false
positivity and false negativity rate of AFB slide readings at health
facilities against the EQA center readings in the study area were
found to be 0.19% and 0.17% respectively (Unpublished data,
Management Sciences for Health, 2015).
2.2. Identiﬁcation of index TB cases and their household contacts
We trained TB focal persons in the eleven health centers on
the data collection, symptomatic screening, sputum sample
collection and referral. New AFB sputum smear positive patients
diagnosed in the 11 health centers during the study period who
had at least one household family member were included in the
study. Once the patient was diagnosed, the address of the patient
was recorded. The contact details of 119 consecutive smearpositive index TB cases were noted. All index cases were either
asked to bring their household contacts to the health center or
visited at home by the study team composed of supervisors and
community health workers called health extension workers
(HEW) within 2 weeks of diagnosis. Household contact was
deﬁned as a person who shared the same enclosed living space
for one or more nights or for frequent or extended periods during
the day with the index case during the 3 months before
commencement of the current treatment episode9. TB focal
persons and both urban and rural HEWs were involved in
registering the household contacts and screening of contacts for
symptoms suggestive of TB.
2.3. Data collection and TB symptom screening
A baseline data was ﬁlled in a standardized questionnaire for
each index smear positive TB case by the TB focal person in the
health centers. The major information collected was socio-
demographic data, signs and symptoms, duration of illness,
contact history and the laboratory results. A family matrix form
was used to register all household contacts. A standard question-
naire was administered by the TB focal person or HEWs to each
household contact independently that included socio-demograph-
ic characteristics and relationship status to the index case. The TB
focal person or HEWs registered the household contacts and
screened them for the major signs and symptoms of TB. Household
contacts with history of cough for two or more weeks or with two
or more symptoms suggestive of TB were considered to have
presumptive TB8. Presumptive TB cases were referred to the health
center for further evaluation and laboratory investigation (ZN
microscopy and GeneXpert).
2.4. TB diagnosis
Three sputum samples (Spot-Morning-Spot) were collected at
the health centers from each household contact with presumptive
TB. Morning sputum specimens were also collected from the
119 index TB cases for GeneXpert test. All the 119 index TB cases
were already put on ﬁrst line anti-TB drug treatment based on the
ZN microscopy result and continued the treatment even if the
GeneXpert test result turned out negative. The TB focal persons in
the respective health centers transported the sputum samples to
Gondar University hospital following the standard infection
control and specimen transportation procedures (using cold
box) for GeneXpert test. Trained senior laboratory personnel in
the health centers and Gondar University hospital were engaged in
conducting the ZN microscopy and GeneXpert tests, respectively.
The laboratory personnel doing ZN microscopy and GeneXpert
MTB/RIF test were blinded. The three samples from contacts were
tested for AFB by ZN sputum smear microscopy and GeneXpert test
was also done on the morning sputum sample. In addition,
GeneXpert test was done on the morning sputum specimens
collected from the index TB cases.
2.5. Data analysis
Data entry and analysis was performed using SPSS, Version 13
(SPSS Inc., Chicago, Illinois). Data was entered by an experienced
data clerk under the supervision of the principal investigator.
Frequency, percentage and 95% conﬁdence interval of proportions
were computed. The number needed to screen (NNS) and number
needed to test (NNT) was also computed. NNS is the number of
contacts required to be screened to detect a single case of active TB;
NNT is the number of contacts with presumptive TB required to be
investigated in the laboratory to detect a single case of active TB.
The 95% conﬁdence intervals of proportion among different
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intervals is considered as a statistically signiﬁcant difference.
2.6. Ethical considerations
Ethical approval was obtained from the University of Gondar
ethical review board [reference number RCS/P/05/485/2013 dated
June 4th 2013]. Each study participant provided a written informed
consent and permission was obtained from all health facilities.
Written parental consent was also obtained for participants below
the age of 18 years. Household contacts with positive TB result
were treated in accordance with the national tuberculosis program
recommendations11. Rifampicin resistant results by GeneXpert
test were immediately communicated to each health centers for
proper management of patients as per the national tuberculosis
program recommendations11.
3. Result
3.1. Characteristics of index cases
A total of 119 newly diagnosed index TB cases were registered
during the study period. They were sputum smear positive by the
ZN staining done in the laboratory of the respective health center.
The index cases lived in 119 different households. Two-thirds of
the index cases were urban residents and the male to female ratio
was 1.38. Four-ﬁfths of the index cases were in the age range 15 to
44 years with mean (SD) age of 31.2 (14.1) years (Table 1). Only 6
(5%) had past history of TB. GeneXpert MTB/RIF test was done for
all index TB cases. The GeneXpert test among index TB cases
revealed that 8/119 (6.7%) were negative for TB while 106/119
(89.1%) and 5/119 (4.2%) were rifampicin sensitive and rifampicin
resistant TB, respectively.
3.2. The yield of active TB case ﬁnding among household contacts
A total of 393 contacts were identiﬁed in 119 households with
contact to index TB cases ratio of 3.3. The contacts were between
1 and 94 years of age with Mean (SD) age of 24.6 (18.2). Out ofTable 1
Socio-demographic characteristics of smear positive index
tuberculosis cases
Characteristics Frequency (%)
Residence
Rural 44 (37.0)
Urban 75 (63.0)
Gender
Male 69 (58.0)
Female 50 (42.0)
Age in years
12-14 5 (4.2)
15-24 39 (32.8)
25-34 35 (29.4)
35-44 22 (18.5)
45+ 18 (15.1)
Educational background
No formal education 48 (40.3)
Primary education 24 (20.2)
Secondary education 40 (33.6)
Diploma and above 7 (5.9)
Occupation
Farmer 25 (21.2)
Government employee 7 (5.9)
Domestic work 9 (7.6)
Petty trade 3 (2.5)
Daily laborer 32 (27.1)
Driver 5 (4.2)
Student 29 (24.6)
Other 9 (7.6)393 contacts, 353 (89.8%) were screened for symptoms suggestive
of tuberculosis. A total of 41 (11%) of the screened contacts were
found to have presumptive TB of which all with the exception of
two under-ﬁve children were checked with ZN microscopy (spot-
morning-spot) and GeneXpert MTB/RIF test. Of 39 presumptive TB
cases with sputum samples, GeneXpert test diagnosed 14 (35.9%)
cases of TB whereas the number of TB cases diagnosed by ZN
microscopy was 5 (12.8%): a 64.3% increased positivity rate by
GeneXpert versus ZN microscopy. The entire ﬁve cases positive by
ZN microscopy were also positive for TB in the GeneXpert test. Two
under-ﬁve children were diagnosed clinically and using X-ray as
smear negative pulmonary TB cases (Figure 1). Of the 14 bacterio-
logically conﬁrmed TB cases, one was found to be rifampicin
resistant TB. A total of 108 (90.8%) households did not have any
active TB case among the contacts, 8 households (6.7%) had one TB
case each, 2 (1.7%) households had 2 TB cases each and 1 (0.8%)
household had four TB cases diagnosed among the contacts.
3.3. The prevalence of TB among household contacts
Sixteen cases of tuberculosis were identiﬁed (two clinical and
X-ray diagnosis; and one rifampicin resistant) through the
household TB contact screening with overall prevalence of
4,532.6 per 100,000 contacts: bacteriologically conﬁrmed TB
was 3,966 per 100,000, rifampicin sensitive TB was 3,682.7 per
100,000 and rifampicin resistant TB was 283.3 per 100,000. The
prevalence of TB in rural and urban residence was 4,458.6 and
4,591.8 per 100,000, respectively (p>0.05). The prevalence of TB
among male and female contacts was 4,545.5 and 4,522.6 per
100,000, respectively (p>0.05). TB prevalence per 100,000 ranged
from 2343.8 in the age group 15 to 34 years to 11,111.1 in the age
group 60 years and above (p>0.05). With regard to relationship
status with the index case, the prevalence of TB per 100,000 ranged
from 2702.7 among sibling contacts to 6666.7 among other
relatives (p>0.05) (Table 2).
3.4. Comparison of the performance of GeneXpert MTB/RIF versus ZN
microscopy in TB household contact investigation
The prevalence of TB by using the GeneXpert diagnostic test
was 3966.0 per 100,000 contacts while it was 1416.4 per 100,000
contacts by ZN microscopy. The number of contacts needed to
screen (NNS) to ﬁnd a single case of TB while using GeneXpert as a
diagnostic test was 25 as compared to the 70 while using ZN
microscopy. The number of presumptive TB cases needed to test
(NNT) to diagnose a single case of TB while using GeneXpert was
three and the corresponding number in using ZN microscopy was
eight.
4. Discussion
The performance of GeneXpert MTB/RIF in identifying TB
among household contacts of index cases was signiﬁcantly higher
as compared with ZN microscopy. Out of 14 bacteriologically
conﬁrmed TB cases among household contacts, nine cases (64.3%)
would have been missed if we had relied on ZN microscopy alone.
The number needed to screen and number needed to test to
diagnose a single case of TB was signiﬁcantly lower with the use of
GeneXpert than ZN microscopy indicating the better efﬁciency of
the former laboratory test. ZN microscopy needed three consecu-
tive sputum samples while GeneXpert test was done using a single,
morning sputum sample but with additional diagnostic yield.
Studies have shown that smear microscopy is able to detect TB
in patients with advanced disease who discharge sufﬁcient
number of bacilli18,19. In our study, two-thirds of the TB cases
among household contacts would have remained undiagnosed if
Fig. 1. Active case ﬁnding among household contacts of smear positive index TB cases.
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discharge TB bacilli but couldn’t be detected by the conventional
smear microscopy would continue suffering with the disease and
transmit the disease to their contacts unless we use a more
sensitive test like GeneXpert to enable early identiﬁcation of cases.
Although the use of GeneXpert enabled better case detection
among contacts, the wider use of GeneXpert in low income settings
needs to be evaluated in terms of its cost-effectiveness, feasibility
and the priority group to be targeted by the service16,17. Further
clinical characterization of subsets of presumptive TB cases among
TB contacts who would beneﬁt most from GeneXpert MTB/ RIF
testing could help to optimize its use in settings with limited
resources.
Signiﬁcant proportions of smear positive index TB cases by ZN
microscopy were also conﬁrmed positive by GeneXpert which
signiﬁes the quality of ZN microscopy service in the health centers.
Eight (6.7%) of the already smear positive index TB cases (ZN
microscopy) were negative for TB in the GeneXpert test. The
incongruity can be attributed to either a false positive result by
the ZN microscopy even though the EQA false positivity rate in the
study area was 0.19% or the bacilli might have been mycobacteria
other than tuberculosis as the GeneXpert only detects Mycobacte-
rium tuberculosis complex strains. Rifampicin resistant TB, a
surrogate marker for MDR-TB, was also diagnosed among 5
(4.2%) index cases who were put on ﬁrst line anti-TB drugs based
on ZN microscopy result alone at the health centers. It would have
taken time for the health centers to suspect drug resistance TB in
the course of ﬁrst line treatment and consider drug susceptibility
testing (DST). The rifampicin resistant TB burden among index
cases in our study is greater than the 2.3% rate of MDR-TB (resistant
to at least rifampicin and isoniazid) among new cases of TB and less
than the 17.8% rate reported in previously treated TB cases in the
national TB drug resistance survey20. One of the components of the
End TB strategy emphasized on early diagnosis of tuberculosisincluding universal drug-susceptibility testing which is also
supported by the ﬁndings of this study21.
Although GeneXpert test has a cost implication, a single sputum
test using GeneXpert would have improved the diagnostic
capacity, reduced the number of sputum samples to be collected
and enabled the immediate identiﬁcation of drug resistant TB. A
survey done in 24 countries in 2015 revealed that 8 countries,
including Swaziland and South Africa from Africa, adopted
GeneXpert test as a ﬁrst line diagnostic test in the diagnosis of
TB replacing smear microscopy22. It is advisable that countries like
Ethiopia learn from the experience of countries that are using
GeneXpert as a ﬁrst line test for possible scale up of the GeneXpert
test. There is a critical need for operational research to understand
the pros and cons of decentralizing GeneXpert MTB/RIF test at the
district level16.
There were two households with four and two TB cases
diagnosed among the contacts. It appears that there were
households who had higher risk of transmission with resultant
clustering of TB cases in the households. The clustering of TB cases
in a household is more likely to be due to shared risk factor rather
than individual level risk factor such as nutritional status,
ventilation, air pollution or any other factor shared by household
members23–26. Further analysis on the factors that fueled the TB
transmission in those households was not done. There is a need to
strengthen community TB care to ensure early diagnosis and
treatment of index TB cases and reduce the risk of transmission to
household and close contacts. TB infection control at household
level is also an area that can be improved by educating community
members regarding TB transmission, prevention and earlier health
care seeking.
The overall prevalence of tuberculosis among household
contacts using GeneXpert was 3,966 per 100,000 which is 20 fold
of the estimated national prevalence of TB1. There was no
signiﬁcant difference in the diagnosis of TB among household
Table 2
Prevalence of TB among contacts by socio-demographic characteristics
Characteristics Number of contacts Number of presumptive
TB (Row %)
Prevalence of TB diagnosis per 100,000;
N (prevalence: 95% CI)a
Overall 353 41 (11.6%) 16 (4.5:2.8, 7.2)b,c
Residence
Rural 157 13 (8.3%) 7 (4.4: 2.2, 8.9)
Urban 196 28 (14.3%) 9 (4.6: 2.4, 8.5)
Gender
Male 154 15 (9.7%) 7 (4.5: 2.2, 9.1)
Female 199 26 (13.1%) 9 (4.5: 2.4, 8.4)
Age in years
0-4 25 5 (20.0%) 2 (8.0: 2.2, 2.5)
5-14 106 10 (9.4%) 6 (5.7: 2.6, 1.2)
15-34 128 17 (13.3%) 3 (2.3: 0.8, 6.7)
35-59 67 6 (9.0%) 2 (2.9: 0.8, 10.2)
60 & above 27 3 (11.1%) 3 (11.1: 3.9, 28.1)
Educational background
No formal education 147 18 (12.2) 12 (8.2: 4.7,13.7)
Primary education 97 13 (13.4) 4 (4.1: 1.6, 10.1)
Secondary education 56 9 (16.1) -
Diploma and above 11 1 (9.1) -
Marital status
Single 217 26 (12.0) 9 (4.1: 2.2, 7.7)
Married 112 11 (9.8) 4 (3.6: 1.4, 8.8)
Divorced 10 1 (10.0) 1 (10.0: 1.8, 40.4)
Separated 2 0 -
Widowed 12 3 (25.0) 2 (16.7: 4.7,44.8)
Relation to index
Head/ Spouse 93 8 (8.6%) 4 (4.3: 1.7, 10.5)
Son/Daughter 117 14 (12.0%) 7 (5.9: 2.9, 11.8)
Parent 33 4 (12.1%) 1 (3.0: 0.5, 15.3)
Sibling 74 8 (10.8%) 2 (2.7: 0.7, 9.3)
Other relative 30 5 (16.7%) 2 (6.7: 1.8, 21.3)
Non-relative 6 2 (33.3%) -
a prevalence & 95% CI in thousands
b One case is RR TB
c Two cases are clinical diagnosis of TB
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the index case. However it is worth noting that the diagnosis of TB
in the contacts was made largely based on laboratory conﬁrma-
tion except the two Pediatric cases diagnosed clinically and using
X-ray. It is likely that more cases of clinical and extra-pulmonary
TB might have been diagnosed subsequently from the presump-
tive TB cases which were not captured here due to the cross
sectional nature of this study. It could have led to possible
underestimation of the prevalence of all forms of TB among the
household contacts.
The study needs to be interpreted with the following limitations
in mind. The study did not consider some risk factors like HIV
status of study participants and the condition of households, and
the associated risk in the development of TB. The study also did not
include the gold standard culture test to evaluate the sensitivity
and speciﬁcity of ZN and GeneXpert test results. The use of
standard operating procedures, availability of quality assurance
mechanisms in the laboratories and involvement of highly
qualiﬁed laboratory personnel are amongst the strengths of this
study.
Our ﬁndings suggest that GeneXpert MTB/RIF test could lead to
increased TB case detection among household contacts in addition
to its advantage in the diagnosis of rifampicin resistant TB among
contacts. The use of GeneXpert also helped in the identiﬁcation of
rifampicin resistant TB among newly diagnosed index TB cases in
the health centers. There should be a consideration in using
GeneXpert MTB/RIF as a point of care TB testing tool among high
risk groups such as contacts especially in settings like Ethiopia
where the burden of TB is high. Further study is recommended to
analyze the cost-effectiveness and feasibility of scaling up
GeneXpert as a ﬁrst line test.Acknowledgements
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